Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Work In Process (2018 - 2025)

Immucell's Work In Process history spans 8 years, with the latest figure at $5.7 million for Q4 2025.

  • For Q4 2025, Work In Process changed 0.04% year-over-year to $5.7 million; the TTM value through Dec 2025 reached $5.7 million, changed 0.04%, while the annual FY2025 figure was $5.7 million, 0.04% changed from the prior year.
  • Work In Process reached $5.7 million in Q4 2025 per ICCC's latest filing, down from $6.0 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $6.1 million in Q3 2024 to a low of $1.4 million in Q1 2021.
  • Average Work In Process over 5 years is $5.1 million, with a median of $5.6 million recorded in 2024.
  • Peak YoY movement for Work In Process: soared 69.55% in 2021, then dropped 2.81% in 2025.
  • A 5-year view of Work In Process shows it stood at $1.4 million in 2021, then skyrocketed by 142.14% to $3.5 million in 2022, then surged by 67.65% to $5.8 million in 2023, then fell by 1.18% to $5.7 million in 2024, then rose by 0.04% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Work In Process are $5.7 million (Q4 2025), $6.0 million (Q3 2025), and $5.6 million (Q2 2025).